推薦產品
等級
pharmaceutical primary standard
API 家族
triamterene
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
InChI
1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
InChI 密鑰
FNYLWPVRPXGIIP-UHFFFAOYSA-N
基因資訊
human ... SCNN1A(6337) , SCNN1B(6338) , SCNN1G(6340)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Triamterene EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險分類
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
[Pharmacology of potassium-sparing diuretics: amiloride and triamterene].
G Rorive et al.
Coeur et medecine interne, 17(2), 207-215 (1978-04-01)
R A Carey et al.
Clinical therapeutics, 6(3), 302-309 (1984-01-01)
A small number of patients taking products containing triamterene (TAT) develop renal calculi that contain TAT and its metabolites. Most TAT-containing calculi are composed of various crystalline materials, but a small number consist only of TAT, its metabolites, and a
D A Sica et al.
Nephron, 51(4), 454-461 (1989-01-01)
Triamterene (TA) is a mild 'potassium-sparing' diuretic usually employed in combination with other more potent diuretics in the treatment of hypertension. TA pharmacokinetics and pharmacodynamics in normal volunteers, elderly subjects and in patients with renal and hepatic dysfunction are reviewed.
C Lucas et al.
Journal d'urologie, 88(1), 37-42 (1982-01-01)
Various studies have demonstrated a relationship between nephrolithiasis and the ingestion of certain drugs. We are particularly interested in the effects of triamterene. Five published case studies on patients of both sexes between 43 and 60 years of age have
A Haris et al.
Orvosi hetilap, 137(35), 1907-1914 (1996-09-01)
The group of drugs, so-called "potassium sparing diuretics" represent an important part of our modern therapeutic arsenal. Their "weak diuretic" properties are especially beneficial in cirrhotic patients with ascites, when highly effective loop diuretics may be hazardous. Potassium sparing diuretics
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務